Olavide Neuron STX (ONESTX)
Exhibitor
ONESTX leverages the biology of aging to treat incurable neurodegenerative conditions. Our lead oral compound, LON-21, restores the brain's youthful neurosteroid profile by irreversibly inhibiting the STS enzyme, driving neuroprotection and synaptic plasticity. Highly de-risked with established human safety from previous clinical trials, LON-21 is advancing toward Phase IIa trials for Huntington’s Disease. Having officially secured Orphan Drug Designation (ODD) from the FDA for Huntington's, ONESTX is accelerating clinical proof-of-concept while ensuring robust intellectual property protection and market exclusivity. ONESTX is actively seeking lead investors for our Series A round to advance our Phase IIa clinical programs
Created by
Terrapinn is proud to be a member of isla.
Working together to build sustainable events